Unichem Laboratories Ltd. — Interim / Quarterly Report 2023

Nov 12, 2022

==> picture [190 x 43] intentionally omitted <==

November 12, 2022

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001

Scrip Code: 506690

National Stock Exchange of India, Exchange Plaza, 5[th] Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Scrip Code: 506690

Dear Sir/Madam

Sub.: Financial Results for Second quarter and Six months ended September 30, 2002 published in newspapers on November 12, 2022 .

Pursuant to Regulation 47 of the Listing Regulations, please find attached copies of the Financial Results for the second quarter and six months ended September 30, 2022 published in the following newspapers on November 12, 2022 .

1. Mumbai edition of Business Standard

2. Mumbai edition of Sakal

This is for your information and record.

Thanking you,

For UNICHEM LABORATORIES LIMITED

==> picture [90 x 86] intentionally omitted <==

PRADEEP Digitally signed by PRADEEP BHANDARI BHANDARI Date: 2022.11.12 18:25:43 +05'30' PRADEEP BHANDARI Head- Legal & Company Secretary

==> picture [189 x 32] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.

20

1

MUMBAI | 12 NOVEMBER 2022

~~>~~

~~l~~

Extract of Statement of Unaudited Consolidated Financial Results for the Three and Six Months Ended September 30, 2022	Extract of Statement of Unaudited Consolidated Financial Results for the Three and Six Months Ended September 30, 2022
Particulars Total Income from Operations (net) Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items) Net Profit / (Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items) Net profit / (Loss) for the period after tax (after Exceptional and Extraordinary items) Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax) Paid up Equity Share Capital (Face value of Rs.5/- each) Other Equity Earnings Per Share of Rs. 5/- each Basic Diluted	(Rs. in Lakhs, except per share data) Three months ended 30/09/2022 Preceeding Three months ended 30/06/2022 Corresponding Three months ended 30/09/2021 Year to date figures for current period ended 30/09/2022 Year to date figures for previous period ended 30/09/2021 Previous year ended 31/03/2022 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 425107 32707 32707 21284 25428 14.19 14.19 22.05 17.24 379560 25428 32378 371707 804667 747728 68811 98222 76809 22.05 17.24 7189 554345 73.42 73.42 38299 38299 26741 20653 32740 76261 1466264 129127 158538 110836 109864 25965 36.24 36.24 51.26 51.26 58135 58135 53662 53393
*** Not Annualised Notes:**

1. The consolidated financial information of Apollo Hospitals Enterprise Limited (“the Company”) for the three and six months ended September 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 9, 2022 and Novembe 10, 2022 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three and six months ended September 30, 2022 . These consolidated financial results have been extracted from the consolidated financial information.

2. Unaudited financial results of Apollo Hospitals Enterprise Limited (standalone information)

Particulars Discontinued Operations Continuing Operations Revenue from Operations Profit Before Tax Profit after tax for the period Revenue from Operations Profit Before Tax Profit after tax for the period Profit after tax for the period from continuing and discontinued operations Total Comprehensive Income for the period [comprising Profit/ (Loss) for the period (after tax) & Other Comprehensive Income (after tax)]	Three months ended 30/09/2022 Unaudited 171558 27919 27315 34559 27919	Unaudited Preceeding Three months ended 30/06/2022 152969 33314 33656 25012 33314	Unaudited Corresponding Three months ended 30/09/2021 165608 116712 3760 2446 18589 18081 25143 16143	Year to date figures for current period ended 30/09/2022 324527 61233 60971 59571 61233 Unaudited	Year to date figures for previous period ended 30/09/2021 313880 41788 26829 267912 10398 6764 33593 33125 Unaudited	Previous year ended 31/03/2022 609833 85213 57234 513139 14248 9269 66503 66279 Audited

1. The above is an extract of the detailed format of financial results for the three and six months ended September 30, 2022 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www. nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.

2. The Company has exercised the option of lower tax permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 ('the Amendment Act"). Accordingly, the Company has recognised provision for income tax for the quarter and six months ended September 30, 2022 basis the rate provided in the said Amendment Act. The Company has re-measured the opening balance of Deferred Tax Liability (net) as at April 1, 2022 and accounted tax credit of Rs. 14,659 lakhs relating to the same in the previous quarter

3. The Company had received approval from the Regional Director, Ministry of Corporate Affairs on June 28, 2021 for the Scheme of Amalgamation with the following wholly owned subsidiary companies, with the Appointed Date being April 1, 2020:

a. Apollo Home Healthcare (India) Limited and

b. Western Hospitals Corporation Private Limited

Consequent to giving effect to the said Scheme of Amalgamation, the Company had created a provision against loan of Rs. 674 lakhs extended by Western Hospitals Corporation Private Limited to its subsidiary Apollo Lavasa Health Corporation Limited. This provision was disclosed under Exceptional Items in the standalone financial results for the year to date September 30, 2021 and year ended March 31, 2022

1. The Company in the year ended Mar 31, 2022 reorganised its pharmacy distribution by transferring to Apollo Healthco Limited, a wholly owned subsidiary of the Company

2. Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs.

The utilisation of the QIP Issue proceeds upto September 30, 2022 is as follows:

Particulars Amount in Rs. Lakhs Fees paid to Lead Managers 1,785.00 Foreclosure of debts 25,138.00 Acquisition of equity stake in Apollo Multi Speciality Hospitals Limited 41,000.00 Acquisition of equity stake in Apollo Hospitals North Limited 27,500.00 Loan given to Apollo Hospitals North Limited 21,576.00

1. The Company has executed definitive agreements on 5th October 2022 in connection with the acquisition of a 60% equity stake in Kerala First Health Services Private Limited (“KFHSL”), which offers quality systems driven Ayurveda medical care services under the “AyurVAID Hospitals” brand through a combination of primary and secondary equity investment with the overall transaction consideration of Rs. 2,640 lakhs.

The primary investment will be used to upgrade existing centres, set up new centres, strengthen enterprise platforms, and for digital health initiatives. Consequent to this acquisition, KFHSL would become a subsidiary of the Company

1. The Company had invested an amount of Rs. 27,500 lakhs in the equity capital of Apollo Hospitals North Limited (wholly owned subsidiary company) and also provided an unsecured loan amount of Rs. 21,576 lakhs for its expansion activities.

2. Apollo Hospitals North Limited, wholly owned subsidiary of the Company has completed the acquisition of the assets forming part of a 650 bedded potential hospital facility, which was being set up by Nayati Healthcare and Research NCR Private Limited in Gurgaon for a consideration of about Rs 47,587 lakhs (incl Stamp Duty & other incidental charges)

3. The Company completed the acquisition of an additional 50% stake held by Gleneagles Development Pte Limited (erstwhile joint venturer) in Apollo Multi Specialty Hospitals Limited (AMSHL) (formerly known as Apollo Gleneagles Hospitals Limited), Kolkata on April 22, 2021 for a consideration of Rs. 41,000 lakhs. Consequently, AMSHL became a wholly owned subsidiary of the Company and has been consolidated effective from April 22, 2021. The resultant goodwill of Rs. 53,714 lakhs has been presented within the Healthcare segment.

The acquisition date fair value of the existing equity interest in AMSHL compared to its carrying amount resulted in a gain of Rs. 29,411 lakhs, which has been included under exceptional items

1. On November 12, 2021, Assam Hospitals Limited, a subsidiary company of the Group had acquired 64.42% shareholding in Asclepius Hospitals & Healthcare Private Limited.

Based on the information available at March 31,2022, the Subsidiary Company determined a preliminary purchase price allocation based on the provisional amounts of the identifiable assets acquired and liabilities assumed, resulting in a provisional goodwill of Rs. 1,153 lakhs as at March 31, 2022, subject to finalisation of the purchase accounting. As at September 30, 2022 on receipt of complete information the purchase accounting is finalised, resulting in increase in the goodwill balance to Rs. 2,795 lakhs

1. The Honourable High Court of Karnataka on October 8, 2021 had set aside the order of the State of Karnataka, Revenue Department ("Revenue Department") initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company alleging non-compliance of certain conditions associated with the allotment of land to the said subsidiary company and have remitted it back to the Revenue Department for reconsideration and disposal. The Revenue Department had issued a show cause notice dated 9 February 2022 seeking explanations as to why the original order needs to be withdrawn for which the subsidiary company had filed a detailed response explaining there were no violations of the conditions relating to the allotment of the land. Based on legal opinion received, the subsidiary company has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in their favour

2. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

Place : Chennai Date : 10th November, 2022

for APOLLO HOSPITALS ENTERPRISE LIMITED

DR. PRATHAP C REDDY

Executive Chairman

==> picture [327 x 519] intentionally omitted <==

==> picture [326 x 519] intentionally omitted <==

==> picture [327 x 519] intentionally omitted <==

==> picture [327 x 520] intentionally omitted <==

==> picture [326 x 520] intentionally omitted <==

==> picture [327 x 520] intentionally omitted <==

==> picture [327 x 519] intentionally omitted <==

==> picture [326 x 519] intentionally omitted <==

==> picture [327 x 519] intentionally omitted <==

Back